Skip to main content
. 2006 Mar;80(6):2738–2746. doi: 10.1128/JVI.80.6.2738-2746.2006

FIG. 5.

FIG. 5.

Demonstration of the bivalency of the cAdVaxE(GPs/z) vaccine, in comparison to the monovalent cAdVaxE(GPs) and cAdVaxE(GPz) vaccines. Mice were vaccinated as described in the legend to Fig. 4. Vaccinated mouse sera from mice immunized with cAdVaxE(GPs/z), cAdVaxE(GPs), cAdVaxE(GPz), or HC4 control were harvested on week 38 and assayed for anti-SEBOV GP and anti-ZEBOV GP antibodies by ELISA. Statistically significant differences (P < 0.05) were determined by using a one-tailed, paired t test. GP, glycoprotein; SEBOV, Sudan ebolavirus; ZEBOV, Zaire ebolavirus; Ab, antibody; *, statistically significant difference from HC4 control vaccinations; **, statistical difference between the anti-SEBOV GP and anti-ZEBOV GP antibody titers induced by an individual vaccine; ***, statistical difference between bivalent cAdVaxE(GPs/z) GP titers and cAdVaxE(GPz) anti-ZEBOV GP titers; †, statistically significant difference from cAdVaxE(GPs) anti-ZEBOV GP (heterologous GP) titers; ††, statistically significant difference from cAdVaxE(GPz) anti-SEBOV GP (heterologous GP) titers.